Pesticide makers stack wins against US environmental, public health groups

• The Supreme Court ruled 7-2 that plaintiffs cannot sue Bayer under state laws for failing to warn about glyphosate cancer risks, potentially ending consolidated litigation involving nearly 4,000 lawsuits that threatened the product's viability
• Dicamba was re-approved by the EPA in February 2026 for two growing seasons with new restrictions after a 2024 court ruling had vacated its registration and prevented use in 2025
• The U.S. Fish and Wildlife Service concluded in April 2026 that atrazine does not pose extinction risk to studied species, reversing the EPA's 2021 finding that it would adversely affect over 1,000 protected species, despite WHO classifying it as 'probably carcinogenic to humans' in 2025

Market Summary: Pesticide Industry Secures Regulatory Victories

Key Developments:

The U.S. pesticide industry has secured multiple regulatory and legal wins in recent months, led by Bayer's major Supreme Court victory in June 2026. In a 7-2 decision on June 25, the Court significantly limited lawsuits against Bayer regarding glyphosate (Roundup's active ingredient) and cancer risk warnings. Bayer subsequently moved to dismantle litigation consolidating nearly 4,000 cancer-related lawsuits, which threatened the company's ability to continue selling the weedkiller.

Companies and Products:

• Bayer (acquired Monsanto in 2018): Glyphosate/Roundup and dicamba
• Syngenta: Dicamba and atrazine

Additional Regulatory Wins:

• Dicamba: Re-approved in February 2026 for two growing seasons with new restrictions, including reduced application rates and weather limitations, after farmers were unable to use it in 2025 following a court vacating prior EPA approvals
• Atrazine: U.S. Fish and Wildlife Service concluded in April 2026 that the herbicide poses no extinction risk to studied threatened/endangered species, reversing the EPA's 2021 evaluation that found adverse effects on over 1,000 protected species

Political Context:

The Trump administration sided with Bayer, creating friction with RFK Jr.'s "Make America Healthy Again" movement. Environmental groups claim the administration favors large agricultural and pesticide companies over public health, marking a significant shift from the Biden administration's more cautious approach.

Health Concerns:

The WHO's International Agency for Research on Cancer classified atrazine as "probably carcinogenic to humans" in 2025. Studies suggest possible links to cancer and pre-term births.

Market Implications:

These victories provide regulatory clarity and reduce litigation risk for major agrichemical companies, supporting continued pesticide sales in a key agricultural market.